The effectiveness of a remote or telemedical initiative that reaches out to patients in their homes may increase as new technology makes essential care tasks easier for practices to process.
Tasso Inc. is developing a product for testing blood that could become a new standard for efficiency. The University of Wisconsin-Madison News reported on this development and the microfluidics technology it uses to easily draw blood into a small device attached to a patient's arm.
Ben Casavant, Tasso's co-founder, said the device could reach the market some time next year. Casavant hopes to reduce the cost and general difficulties usually associated with similar, far more complicated blood testing systems.
While the article didn't mention telemedicine or remote care specifically, Casavant did emphasize the ease of use that the device could lead to, especially with $3 million in funding from the Defense Advanced Research Projects Agency (DARPA). DARPA is also supporting technology that would enable blood to be transported, with greater implications for widespread use.
"We see our specialty as people who need to test semi-frequently, or infrequently, to monitor cancer or chronic infectious diseases, for example," he said. "Instead of buying a machine or expensive equipment, we ship you this device, you put it on your arm for two minutes and send it back to the lab."
Mobile device apps and initiatives that promote off-site care may encourage practices to integrate them into regular practices. However, without oversight from healthcare IT consulting services, health entities may launch a new program incorrectly and leave themselves at risk of improper data use and behaviors.
Professional training and guidance will make using novel devices less of a liability, because the members of a health organization will be better trained to follow a prescribed policy.